FDA authorized Cue Health’s COVID-19 test for at-mome and Over The Counter Use
On Mar. 5, 2021, Cue Health announced it had received Emergency Use Authorization (EUA) from the U.S. Food…
Abivax stopped phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy
On Mar. 5, 2021, Abivax announced tthat it was halting the miR-AGE phase 2b/3 clinical trial in high-risk…
Ridgeback Biotherapeutics and Merck announced preliminary findings from phase 2a trial of investigational COVID-19 therapeutic
On Mar. 5, 2021, Merck and Ridgeback Biotherapeutics, announced preliminary results from Ridgebackﾒs Phase 2a randomized, double-blind, placebo-controlled…
CureVac and Novartis signed initial agreement on manufacturing of COVID-19 vaccine candidate, CVnCoV
On Mar. 4, 2021, CureVac and Novartis announced an initial agreement for the manufacturing of CureVacﾒs COVID-19 vaccine…
NIH-sponsored ACTIV-3 clinical trial closed enrollment into two sub-studies
On Mar. 4, 2021, the NIH announced that the ACTIV-3 clinical trial evaluating the safety and efficacy of…
New evidence COVID-19 antibodies, vaccines less effective against variants
On Mar. 4, 2021, researchers at the University School of Medicine in St. Louis announced that three new,…
Soligenix announced positive progress in pre-clinical development of its COVID-19 vaccine
On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVaxﾙ (heat stable COVID-19 vaccine program)…
Men, older adults and smokers more prone to infection by SARS-CoV-2
On Mar. 3, 2021, TGen, an affiliate of City of Hope announced that an in-depth analysis of the…
MediciNova announced it had discontinued development of a SARS-CoV-2 vaccine for COVID-19
On Mar. 2, 2021, MediciNova announced it that given the COVID-19 vaccines currently in use and other vaccines…
NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 2, 2021, NanoViricides reported that NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison…
Innovation Pharma announced publication in Journal Viruses on the anti-SARS-CoV-2 properties of brilacidin
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyﾒs international Phase 2…
Cerecor announced postitive data in phase 2 clinical trial in patients hospitalized with COVID-19 ARDS
On Mar. 2, 2021, Cerecor announced final efficacy data including 60-day mortality from their completed US-based, multi-center (10…
Biden administration announced collaboration between Merck and Johnson & Johnson to expand production of COVID-19 vaccines
On Mar. 2, 2021, the Biden Administration has helped forge a historic manufacturing collaboration between two of the…
COVAX published first round of allocations
On Mar. 2, 2021, The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO,…
NIH halted trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
On Mar. 2, 2021, the NIH halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent…
NIH launched effort to understand MIS-C, range of SARS-CoV-2 effects on children
On Mar. 2, 2021, the NIH announced that it had launched a research effort to understand how SARS-CoV-2,…
CDC’s ACIP issued interim recommendation for use of Ebola vaccine
On Mar. 2, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with Merck’s Ervebo was…
CDC’s ACIP issued interim recommendation for use of Janssen COVID-19 vaccine
On Feb. 28, 2021, after a transparent evidence-based review of all available data, the Advisory Committee on Immunization…
CDC Advisory Committee recommended single-shot COVID-19 vaccine for adults 18 and older in US
On Feb. 28, 2021, Johnson & Johnson announced that the U.S. Centers for Disease Control and Preventionﾒs (CDC)…
Johnson & Johnson single-shot COVID-19 vaccine authorized by US FDA for Emergency Use
On Feb. 27, 2021, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) had issued…
Roche SARS-CoV-2 rapid rntigen test received special approval for at-home patient self-testing in Germany
On Feb. 26, 2021, Roche announced it had been granted special approval by the German Federal Institute for…
Innovation Pharma provided study details for phase 2 clinical trial of Brilacidin in hospitalized COVID-19 patients
On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee…
Johnson & Johnson COVID-19 vaccine candidate recommended for EUA by FDA advisory committee
On Feb. 26, 2021, Johnson & Johnson announced that the FDA Vaccines and Related Biological Products Advisory Committee…
EMA accepted Pfizerﾒs MAA for investigational 20-valent pneumococcal conjugate vaccine
On Feb. 26, 2021, Pfizer announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization…
EMA issued advice on Regeneron’s antibody cocktail (casirivimab with imdevimab) for COVID-19 patients
On Feb. 26, 2021, Regeneron announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
IDMC found clear efficacy for REGEN-COVﾙ in phase 3 COVID-19 outpatient outcomes trial
On Feb. 25, 2021, Regeneron announced changes to the phase 3 trial assessing investigational REGEN-COVﾙ (casirivimab with imdevimab)…
UTSW researchers identified mechanism by which exercise strengthens bones and immunity
On Feb. 25, 2021, scientists at the Childrenﾒs Medical Center Research Institute at UT Southwestern announced they had…
FDA allowed more flexible storage, transportation conditions for Pfizer-BioNTech COVID-19 vaccine
On Feb. 25, 2021, the U.S. Food and Drug Administration announced that it was allowing undiluted frozen vials…
Altimmune commenced enrollment in phase 1 trial of AdCOVID needle-free, single-dose Intranasal COVID-19 vaccine candidate
On Feb. 25, 2021, Altimmune announced that it had commenced enrollment in a Phase 1 clinical trial of…
Chimerix reported promising topline results from first cohort of a randomized COVID-19 trial with DSTAT
On Feb. 25, 2021, Chimerix reported topline results from the first cohort of its randomized, double-blind, placebo-controlled Phase…